TY  - JOUR
PY  - 2017//
TI  - sustained virologic response and adverse effects of peg interferon alfa and ribavirin in the treatment of patients with chronic hepatitis c: a study from Iran
JO  - Novelty Biomed.
A1  - Simin, Shoaei
A1  - Shahnaz, Sali
A1  - Azadeh, Lali
A1  - Mehdi, Karamipour
A1  - Javad, Minooeefar
SP  - 172
EP  - 176
VL  - 5
IS  - 4
N2  - BACKGROUND: Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus [HCV] infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin [PEG-IFNalpha/RBV] is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNalpha/RBV therapy in treating patients infected with HCV in Iranian context<p /> <p>Language: en</p>
LA  - en
SN  - 2345-3346
UR  - http://dx.doi.org/
ID  - ref1
ER  -